Carcinoma in Situ of Bladder
6 clinical trials · Condition
◉ Watch Carcinoma in Situ of Bladder
| Record | Firm | Date |
|---|---|---|
| A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) (NCT05375903) | UroGen Pharma Ltd. | 2022-06-01 |
| Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors. (NCT03335059) | Medical Enterprises Ltd. | 2019-04-04 |
| Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder (NCT02901548) | H. Lee Moffitt Cancer Center and Research Institute | 2017-02-16 |
| Retrospective Chart Review of Valstar (NCT01304173) | Endo USA Inc., a Keenova Therapeutics Company | 2011-03-01 |
Track Carcinoma in Situ of Bladder automatically
Every clearance here is in the API, with alerts when new ones post.